<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="Fast COVID-19 Containment With Trehalose MartinonDaisy1BorgesVanessa F.1GomezAngela C.1ShimadaKenichi12*[], 1Division of" exact="Infectious" post="Diseases and Immunology, Department of Pediatrics, Cedars-Sinai Medical CenterLos"/>
 <result pre="COVID-19 Containment With Trehalose MartinonDaisy1BorgesVanessa F.1GomezAngela C.1ShimadaKenichi12*[], 1Division of Infectious" exact="Diseases" post="and Immunology, Department of Pediatrics, Cedars-Sinai Medical CenterLos Angeles,"/>
 <result pre="rapidly spreading infection. Frontline healthcare workers are succumbing to the" exact="infection" post="in their efforts to save lives. There is an"/>
 <result pre="an urgency to develop treatments for COVID-19, yet there is" exact="limited" post="clinical data on the efficacy of potential drug treatments."/>
 <result pre="reopens. Trehalose, a natural glucose disaccharide, is known to impair" exact="viral" post="function through the autophagy system. Here, we propose trehalose"/>
 <result pre="we propose trehalose as a potential preventative treatment for SARS-CoV-2" exact="infection" post="and transmission. trehalose SARS-CoV-2 COVID-19 prophylaxis autophagy fig-count: table-count:"/>
 <result pre="fig-count: table-count: equation-count: ref-count: page-count: word-count: Introduction The pandemic coronavirus" exact="disease" post="2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus"/>
 <result pre="Introduction The pandemic coronavirus disease 2019 (COVID-19), caused by severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2), has rapidly expanded around"/>
 <result pre="The pandemic coronavirus disease 2019 (COVID-19), caused by severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2), has rapidly expanded around the"/>
 <result pre="pandemic coronavirus disease 2019 (COVID-19), caused by severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2), has rapidly expanded around the globe."/>
 <result pre="accomplished through the use of oxygen therapy, mechanical ventilation in" exact="respiratory" post="failure cases, and hemodynamic support for managing septic shock"/>
 <result pre="ventilation in respiratory failure cases, and hemodynamic support for managing" exact="septic shock" post="(1). Unfortunately, advanced healthcare systems are struggling to keep"/>
 <result pre="and Drug Administration (FDA)-approved treatment that can effectively control SARS-CoV-2" exact="infection" post="and transmission. This review aims to propose trehalose as"/>
 <result pre="resistance, and decreased systolic blood pressure. Therefore, trehalose can induce" exact="systemic" post="benefits that are not associated with an increase in"/>
 <result pre="and safety of trehalose treatment for the prevention of SARS-CoV-2" exact="infection" post="and transmission. Since 1925, several studies aimed to understand"/>
 <result pre="has received attention for its protective properties in neurodegenerative and" exact="metabolic diseases" post="(9â€&quot;12). The protective effects of trehalose were considered to"/>
 <result pre="the transcription factor EB (TFEB) was identified to be the" exact="primary" post="lysosomal biogenesis regulator, as it induces the expression of"/>
 <result pre="maternal diabetes, repressed autophagy in developing neuroepithelium cells leads to" exact="neural tube defects" post="(NTDs) in the developing fetus (20). Trehalose administration restored"/>
 <result pre="protein p62, neural stem cell differentiation, mitophagy, and reticulophagy (22)." exact="Sanfilippo syndrome" post="or mucopolysaccharidosis (MPS) type III is a neurodegenerative lysosomal"/>
 <result pre="p62, neural stem cell differentiation, mitophagy, and reticulophagy (22). Sanfilippo" exact="syndrome" post="or mucopolysaccharidosis (MPS) type III is a neurodegenerative lysosomal"/>
 <result pre="stem cell differentiation, mitophagy, and reticulophagy (22). Sanfilippo syndrome or" exact="mucopolysaccharidosis" post="(MPS) type III is a neurodegenerative lysosomal storage disorder."/>
 <result pre="differentiation, mitophagy, and reticulophagy (22). Sanfilippo syndrome or mucopolysaccharidosis (MPS)" exact="type III" post="is a neurodegenerative lysosomal storage disorder. A mouse model"/>
 <result pre="neurological improvements associated with the clearance of autophagic vacuoles in" exact="neuronal" post="and glial cells, as well as the activation of"/>
 <result pre="of the TFEB transcription network (23). In a model of" exact="myocardial infarction" post="cardiac remodeling, the use of trehalose resulted in an"/>
 <result pre="effects (24). Trehalose administration also inhibited and attenuated high-fat diet-induced" exact="atherosclerosis" post="in mice and rabbits, respectively (25â€&quot;27). Mashhad University of"/>
 <result pre="per week for 12 weeks) as an anti-inflammatory agent against" exact="vascular" post="inflammation and atherosclerosis (clinicalTrials.gov, NCT 03700424). Peripheral arterial disease"/>
 <result pre="12 weeks) as an anti-inflammatory agent against vascular inflammation and" exact="atherosclerosis" post="(clinicalTrials.gov, NCT 03700424). Peripheral arterial disease (PAD) patients are"/>
 <result pre="against vascular inflammation and atherosclerosis (clinicalTrials.gov, NCT 03700424). Peripheral arterial" exact="disease" post="(PAD) patients are associated with vascular complications and increased"/>
 <result pre="NCT 03700424). Peripheral arterial disease (PAD) patients are associated with" exact="vascular" post="complications and increased platelet activation. Reduced glucose oxidation, oxidative"/>
 <result pre="patients are associated with vascular complications and increased platelet activation." exact="Reduced" post="glucose oxidation, oxidative stress, and autophagy are factors that"/>
 <result pre="is currently active (clinicalTrials.gov, NCT 04061070). In the context of" exact="infectious diseases," post="autophagy induction is critical for both innate and adaptative"/>
 <result pre="autophagy is an effective way to control most of intracellular" exact="infections" post="(29). The human immunodeficiency virus (HIV), the pathogen well-known"/>
 <result pre="way to control most of intracellular infections (29). The human" exact="immunodeficiency" post="virus (HIV), the pathogen well-known for evading immune responses,"/>
 <result pre="fact that CD4+ T lymphocytes are the predominant target for" exact="HIV infection," post="it is the HIV-infected innate immune cells that make"/>
 <result pre="study has shown that trehalose can restore autophagy impaired by" exact="HIV infection" post="in peripheral blood mononuclear cells (PBMCs) in vitro (Table"/>
 <result pre="has shown that trehalose can restore autophagy impaired by HIV" exact="infection" post="in peripheral blood mononuclear cells (PBMCs) in vitro (Table"/>
 <result pre="that trehalose can restore autophagy impaired by HIV infection in" exact="peripheral" post="blood mononuclear cells (PBMCs) in vitro (Table 1) (32)."/>
 <result pre="in its ability to induce autophagy significantly. Trehalose inhibited HCMV" exact="viral" post="gene expression and viral spread in multiple cell types"/>
 <result pre="induce autophagy significantly. Trehalose inhibited HCMV viral gene expression and" exact="viral" post="spread in multiple cell types (34). Both pre- and"/>
 <result pre="infected cells that trehalose alters the intra-multivesicular bodies (MVBs) virion" exact="morphology" post="and redirects the trafficking of viral vacuole maturation through"/>
 <result pre="intra-multivesicular bodies (MVBs) virion morphology and redirects the trafficking of" exact="viral" post="vacuole maturation through downregulation of Ras-like GTPase 11 (Rab11),"/>
 <result pre="in the control of endosomal trafficking (Figure 1) (33). In" exact="primary" post="mouse cortical cultures infected with the West Nile virus"/>
 <result pre="control of endosomal trafficking (Figure 1) (33). In primary mouse" exact="cortical" post="cultures infected with the West Nile virus (WNV), trehalose"/>
 <result pre="(37) (Table 1). Similar autophagy activation was observed in human" exact="primary" post="airway epithelial cells treated with trehalose, but autophagy induction"/>
 <result pre="1). Similar autophagy activation was observed in human primary airway" exact="epithelial" post="cells treated with trehalose, but autophagy induction impaired antiviral"/>
 <result pre="but autophagy induction impaired antiviral function against human rhinovirus (HRV)" exact="infection" post="(36) (Table 1). Table 1 Summary of antiviral effects"/>
 <result pre="effects by trehalose. Virus Main findings/observations Effective dose References Human" exact="immunodeficiency" post="virus (HIV) Trehalose post-treatment reduced HIV-1 in PBMCs from"/>
 <result pre="100 mM (32) Herpes cytomegalovirus (HCMV) Trehalose altered intra-MVB virion" exact="morphology" post="Trehalose did not change viral DNA synthesis Trehalose increased"/>
 <result pre="(HCMV) Trehalose altered intra-MVB virion morphology Trehalose did not change" exact="viral" post="DNA synthesis Trehalose increased lysosomes Trehalose disrupted Rab11, altered"/>
 <result pre="gene expression and virus production in HFFs, HAECs and in" exact="neuronal" post="culture 50, 100 mM (34) Herpes cytomegalovirus (HCMV) Pre-"/>
 <result pre="Human rhinovirus (HRV) Trehalose increase LC3-II in HRV infected human" exact="primary" post="airway epithelial cells Trehalose reduced IFNi-1 mRNA, and promoted"/>
 <result pre="(HRV) Trehalose increase LC3-II in HRV infected human primary airway" exact="epithelial" post="cells Trehalose reduced IFNi-1 mRNA, and promoted HRV replication"/>
 <result pre="promoted HRV replication 100 mM (36) West Nile virus (WNV)" exact="Viral" post="titer was not changed in vitro at low dose"/>
 <result pre="virus is then internalized and transported through endosomal compartments. The" exact="viral" post="genome is released and used by the host ribosome"/>
 <result pre="is released and used by the host ribosome to synthesize" exact="viral" post="RNA polymerase, thus replicating the viral RNA subgenomes. Viral"/>
 <result pre="host ribosome to synthesize viral RNA polymerase, thus replicating the" exact="viral" post="RNA subgenomes. Viral structural proteins are synthesized and anchored"/>
 <result pre="synthesize viral RNA polymerase, thus replicating the viral RNA subgenomes." exact="Viral" post="structural proteins are synthesized and anchored into the endoplasmic"/>
 <result pre="reticulum (ER). Once the virion is assembled in the ER-Golgi" exact="intermediate" post="compartment (ERGIC) and transferred to the autophagosome, it may"/>
 <result pre="promote amphisome-lysosome fusion for virion degradation after the trafficking of" exact="viral" post="double-membrane vesicles. (2) Trehalose can also activate transcription factor"/>
 <result pre="factor EB (TFEB) and promote lysosome biogenesis. The beta-coronaviruses, severe" exact="acute" post="respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome"/>
 <result pre="EB (TFEB) and promote lysosome biogenesis. The beta-coronaviruses, severe acute" exact="respiratory" post="syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus"/>
 <result pre="(TFEB) and promote lysosome biogenesis. The beta-coronaviruses, severe acute respiratory" exact="syndrome" post="coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV),"/>
 <result pre="beta-coronaviruses, severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East" exact="respiratory" post="syndrome coronavirus (MERS-CoV), encode viral proteins that impair autophagosome-lysosome"/>
 <result pre="severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory" exact="syndrome" post="coronavirus (MERS-CoV), encode viral proteins that impair autophagosome-lysosome fusion,"/>
 <result pre="coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV), encode" exact="viral" post="proteins that impair autophagosome-lysosome fusion, such as the membrane-associated"/>
 <result pre="various viruses hijack the autophagic machinery to the benefit of" exact="viral" post="replication and virion maturation, regulating cellular autophagy with autophagy"/>
 <result pre="or trehalose is of great importance in the treatment of" exact="viral" post="diseases (41). In regard to this, coronaviruses express non-structural"/>
 <result pre="plays an essential role as a SARS-CoVs receptor to mediate" exact="viral" post="entry through endocytosis (Figure 1) (43). Of note, the"/>
 <result pre="SARS-CoV and MERS-CoV in multiple in vitro systems, such as" exact="primary" post="human airway epithelial cell cultures (50, 51). Remdesivir has"/>
 <result pre="in multiple in vitro systems, such as primary human airway" exact="epithelial" post="cell cultures (50, 51). Remdesivir has shown promising results"/>
 <result pre="for remdesivir, sponsored by the National Institute of Allergy and" exact="Infectious" post="Disease, has been completed (clinicalTrials.gov, NCT 04280705) (52). Based"/>
 <result pre="lopinavir-ritonavir treatment alone in alleviating symptoms, shortening the duration of" exact="viral" post="shedding, and hospital stay. However, the lack of a"/>
 <result pre="coronaviral RNA entry into the cytosol, which is required for" exact="viral" post="replication after ACE2-mediated endocytosis (Figure 1) (61). Pre-clinical rationale"/>
 <result pre="erythromycin, macrolide antibiotics, have specific antiviral effects that can inhibit" exact="viral" post="internalization. Oseltamivir-azithromycin combination therapy has been used in randomized"/>
 <result pre="inhibiting SARS-CoV-2 replication in vitro. However, the efficacy diminishes when" exact="symptomatic" post="patients are treated 1 week after the disease's onset."/>
 <result pre="At this point, the patient may have already transitioned from" exact="viral" post="expansion to the inflammatory phase leading to a cytokine"/>
 <result pre="a cytokine storm (67). For instance, during influenza infection, the" exact="viral" post="shedding phase peaks 2â€&quot;3 days after infection (68). A"/>
 <result pre="influenza infection, the viral shedding phase peaks 2â€&quot;3 days after" exact="infection" post="(68). A meta-analysis of randomized controlled trials of oseltamivir"/>
 <result pre="trials of oseltamivir (Tamiflu) indicates that early treatment of the" exact="infection" post="accelerated clinical symptom alleviation and reduced the risks of"/>
 <result pre="infection accelerated clinical symptom alleviation and reduced the risks of" exact="lower" post="respiratory tract complications, suggesting that antiviral drug treatments have"/>
 <result pre="accelerated clinical symptom alleviation and reduced the risks of lower" exact="respiratory" post="tract complications, suggesting that antiviral drug treatments have to"/>
 <result pre="lung caused by a â€œcytokine stormâ€� in patients with COVID-19" exact="infection" post="(clinicalTrials.gov, NCT 04315298) and Swedish Orphan Biovitrum (SOBI) also"/>
 <result pre="stormâ€� in patients with COVID-19 infection (clinicalTrials.gov, NCT 04315298) and" exact="Swedish" post="Orphan Biovitrum (SOBI) also started Anakinra (IL-1 receptor antagonist)"/>
 <result pre="2/3 trials to test their efficacy to reduce hyper-inflammation and" exact="respiratory" post="distress in patients with COVID-19 infection (clinicalTrials.gov, NCT 04324021)."/>
 <result pre="to reduce hyper-inflammation and respiratory distress in patients with COVID-19" exact="infection" post="(clinicalTrials.gov, NCT 04324021). Overall, there are more clinical research"/>
 <result pre="trials in only a few designated hospitals. While the SARS-CoV-2" exact="viral" post="shedding timeline is not well-known, antiviral drugs would be"/>
 <result pre="are no medications or clear guidelines for asymptomatic or mildly" exact="symptomatic" post="patients that test positive (76, 77). These patients must"/>
 <result pre="weeks after reopening (82). Post-pandemic transmission dynamics of SARS-CoV-2 project" exact="recurrent" post="outbreaks during the wintertime and resurgence of this disease"/>
 <result pre="project recurrent outbreaks during the wintertime and resurgence of this" exact="disease" post="may persist for another 3 years (83). Mathematical modeling"/>
 <result pre="with one-time social distancing measures has simulated a resurgence of" exact="infection" post="when social distancing measures were lifted (83). Thus, additional"/>
 <result pre="a large portion of the population would succumb to the" exact="disease" post="(84). The R0, basic reproductive number, represents the transmissibility"/>
 <result pre="(84). The R0, basic reproductive number, represents the transmissibility of" exact="infectious" post="agents in a naive population and can vary depending"/>
 <result pre="of COVID-19. Trehalose could potentially affect cellular organelles required for" exact="viral" post="replication. We would recommend a large community trial comprising"/>
 <result pre="trial comprising of healthy adults, healthcare workers, asymptomatic, and mild" exact="symptomatic" post="COVID-19 patients (Figure 2). The Centers for Disease Control"/>
 <result pre="and mild symptomatic COVID-19 patients (Figure 2). The Centers for" exact="Disease" post="Control (CDC) has recently reported the transmission of SARS-CoV-2"/>
 <result pre="trehalose treatment and stay at home in self-quarantine, as the" exact="secondary" post="attack rate of SARS-CoV-2 transmission within a household is"/>
 <result pre="are confirming cases of children suffering from a severe Kawasaki-like" exact="disease" post="related to COVID-19 (93). This is a significant concern"/>
 <result pre="their education system, and the long term effects of SARS-CoV-2" exact="infection" post="are still unknown in children. Clinical studies on the"/>
 <result pre="oral supplementation of trehalose (100 g/day) for the improvement of" exact="vascular" post="function has been carried out in healthy adults aged"/>
 <result pre="elderly, as a large number of this population suffer from" exact="chronic" post="diseases. By treating healthy adults with trehalose, population-level resistance"/>
 <result pre="By treating healthy adults with trehalose, population-level resistance to the" exact="infection" post="will block the chain of transmission. As a result"/>
 <result pre="be drastically reduced as they are indirectly protected from the" exact="infection" post="(Figure 2) (95). Furthermore, trehalose can activate TFEB and"/>
 <result pre="healthy adults and asymptomatic patients with trehalose would accelerate community" exact="viral" post="containment. Potential Precautions and the Current Limitations for the"/>
 <result pre="and the elderly. We have previously reported that trehalose exacerbated" exact="acute" post="respiratory distress syndrome (ARDS) â€œtwo-hitâ€� murine model (induced by"/>
 <result pre="the elderly. We have previously reported that trehalose exacerbated acute" exact="respiratory" post="distress syndrome (ARDS) â€œtwo-hitâ€� murine model (induced by LPS"/>
 <result pre="We have previously reported that trehalose exacerbated acute respiratory distress" exact="syndrome" post="(ARDS) â€œtwo-hitâ€� murine model (induced by LPS and mechanical"/>
 <result pre="care patients with severe COVID-19, especially those presenting cytokine storm" exact="syndrome" post="or ARDS. For inflammatory cytokines, trehalose has been shown"/>
 <result pre="macrophages (unpublished). As in the clinical practice guidelines by the" exact="infectious diseases" post="society of America on the management of influenza, early"/>
 <result pre="Treating severe COVID-19 patients in the late stage of the" exact="disease" post="would not be sufficient. Instead, other emergency FDA approved"/>
 <result pre="In vitro studies on the effects of trehalose on SARS-CoV-2" exact="infection" post="still need to be investigated since some type of"/>
 <result pre="4.8 g/day for every 60 kgs in humans (96). A" exact="diabetes" post="study used 10 g/day (8), while an acute coronary"/>
 <result pre="(96). A diabetes study used 10 g/day (8), while an" exact="acute" post="coronary artery clinical trial used 2.1 g/day (clinicalTrials.gov, NCT"/>
 <result pre="activate autophagy; however, it is not a good strategy for" exact="viral infection" post="as previously reported (99). Thus, we do not recommend"/>
 <result pre="autophagy; however, it is not a good strategy for viral" exact="infection" post="as previously reported (99). Thus, we do not recommend"/>
 <result pre="considered for fast containment. The investigation of safer treatments for" exact="viral" post="infections should be a continuous priority, as the COVID-19"/>
 <result pre="for fast containment. The investigation of safer treatments for viral" exact="infections" post="should be a continuous priority, as the COVID-19 pandemic"/>
 <result pre="The authors declare that the research was conducted in the" exact="absence of" post="any commercial or financial relationships that could be construed"/>
 <result pre="from a laxative threshold of trehalose and lactulose on healthy" exact="female" post="subjects. Eur J Clin Nutr. (2000) 54:783â€&quot;8. 10.1038/sj.ejcn.160109111083487 4.YoshizaneCMizoteAYamadaMAraiNAraiSMarutaKet"/>
 <result pre="intake on glucose metabolism and incretin secretion in subjects with" exact="Type 2" post="diabetes. Diabetes Care. (2016) 39:e38â€&quot;39. 10.2337/dc15-189126721819 6.HowsonPAJohnstonTHRavenscroftPHillMPSuJBrotchieJMet al.. Beneficial"/>
 <result pre="metabolism and incretin secretion in subjects with Type 2 diabetes." exact="Diabetes" post="Care. (2016) 39:e38â€&quot;39. 10.2337/dc15-189126721819 6.HowsonPAJohnstonTHRavenscroftPHillMPSuJBrotchieJMet al.. Beneficial effects of"/>
 <result pre="on striatal dopaminergic deficits in rodent and primate models of" exact="synucleinopathy" post="in Parkinson's disease. J Pharmacol Exp Ther. (2019) 369:364â€&quot;74."/>
 <result pre="dopaminergic deficits in rodent and primate models of synucleinopathy in" exact="Parkinson's disease." post="J Pharmacol Exp Ther. (2019) 369:364â€&quot;74. 10.1124/jpet.118.25569530918068 7.DeBoschBJHeitmeierMRMayerALHigginsCBCrowleyJRKraftTEet al.."/>
 <result pre="solute carrier 2A (SLC2A) proteins to induce autophagy and prevent" exact="hepatic steatosis." post="Sci Signal. (2016) 9:ra21. 10.1126/scisignal.aac547226905426 8.MizoteAYamadaMYoshizaneCAraiNMarutaKAraiSet al.. Daily intake"/>
 <result pre="prevention of lifestyle-related diseases in individuals with risk factors for" exact="metabolic syndrome." post="J Nutr Sci Vitaminol. (2016) 62:380â€&quot;7. 10.3177/jnsv.62.38028202842 9.TanakaMMachidaYNiuSIkedaTJanaNRDoiHet al.."/>
 <result pre="al.. Trehalose alleviates polyglutamine-mediated pathology in a mouse model of" exact="Huntington disease." post="Nat Med. (2004) 10:148â€&quot;54. 10.1038/nm98514730359 10.AroraAHaCParkCB. Inhibition of insulin"/>
 <result pre="formation and delays pathology in a transgenic mouse model of" exact="oculopharyngeal muscular dystrophy." post="Hum Mol Genet. (2006) 15:23â€&quot;31. 10.1093/hmg/ddi42216311254 12.GaneaE. Harding JJ."/>
 <result pre="and delays pathology in a transgenic mouse model of oculopharyngeal" exact="muscular dystrophy." post="Hum Mol Genet. (2006) 15:23â€&quot;31. 10.1093/hmg/ddi42216311254 12.GaneaE. Harding JJ."/>
 <result pre="exogenous antigen-presentation pathways. Nat Immunol. (2015) 16:729â€&quot;36. 10.1038/ni.319626030023 20.WangFXuCReeceEALiXWuYHarmanCet al.." exact="Protein" post="kinase C-alpha suppresses autophagy and induces neural tube defects"/>
 <result pre="10.1038/ni.319626030023 20.WangFXuCReeceEALiXWuYHarmanCet al.. Protein kinase C-alpha suppresses autophagy and induces" exact="neural tube defects" post="via miR-129-2 in diabetic pregnancy. Nat Commun. (2017) 8:15182."/>
 <result pre="diabetic pregnancy. Nat Commun. (2017) 8:15182. 10.1038/ncomms1518228474670 21.XuCLiXWangFWengHYangP. Trehalose prevents" exact="neural tube defects" post="by correcting maternal diabetes-suppressed autophagy and neurogenesis. Am J"/>
 <result pre="Reprod Toxicol. (2019) 85:51â€&quot;58. 10.1016/j.reprotox.2019.02.00530769031 23.LotfiPTseDYDi RonzaASeymourMLMartanoGCooperJDet al.. Trehalose reduces" exact="retinal degeneration," post="neuroinflammation and storage burden caused by a lysosomal hydrolase"/>
 <result pre="(2019) 85:51â€&quot;58. 10.1016/j.reprotox.2019.02.00530769031 23.LotfiPTseDYDi RonzaASeymourMLMartanoGCooperJDet al.. Trehalose reduces retinal degeneration," exact="neuroinflammation" post="and storage burden caused by a lysosomal hydrolase deficiency."/>
 <result pre="24.SciarrettaSYeeDNagarajanNBianchiFSaitoTValentiVet al.. Trehalose-induced activation of autophagy improves cardiac remodeling after" exact="myocardial infarction." post="J Am Coll Cardiol. (2018) 71:1999â€&quot;2010. 10.1016/j.jacc.2018.02.06629724354 25.StachowiczAWisniewskaAKusKKiepuraAGebskaAGajdaMet al.."/>
 <result pre="(2018) 71:1999â€&quot;2010. 10.1016/j.jacc.2018.02.06629724354 25.StachowiczAWisniewskaAKusKKiepuraAGebskaAGajdaMet al.. The influence of trehalose on" exact="atherosclerosis" post="and hepatic steatosis in apolipoprotein e knockout mice. Int"/>
 <result pre="10.1016/j.jacc.2018.02.06629724354 25.StachowiczAWisniewskaAKusKKiepuraAGebskaAGajdaMet al.. The influence of trehalose on atherosclerosis and" exact="hepatic steatosis" post="in apolipoprotein e knockout mice. Int J Mol Sci."/>
 <result pre="atherosclerosis. Nat Commun. (2017) 8:15750. 10.1038/ncomms1575028589926 27.SahebkarAHatamipourMTabatabaeiSA. Trehalose administration attenuates" exact="atherosclerosis" post="in rabbits fed a high-fat diet. J Cell Biochem."/>
 <result pre="28.KrishnaSMMoxonJVGolledgeJ. A review of the pathophysiology and potential biomarkers for" exact="peripheral artery disease." post="Int J Mol Sci. (2015) 16:11294â€&quot;322. 10.3390/ijms16051129425993296 29.GomesLCDikicI. Autophagy"/>
 <result pre="A review of the pathophysiology and potential biomarkers for peripheral" exact="artery disease." post="Int J Mol Sci. (2015) 16:11294â€&quot;322. 10.3390/ijms16051129425993296 29.GomesLCDikicI. Autophagy"/>
 <result pre="30.KyeiGBDinkinsCDavisASRobertsESinghSBDongCet al.. Autophagy pathway intersects with HIV-1 biosynthesis and regulates" exact="viral" post="yields in macrophages. J Cell Biol. (2009) 186:255â€&quot;68. 10.1083/jcb.20090307019635843"/>
 <result pre="Cell Biol. (2009) 186:255â€&quot;68. 10.1083/jcb.20090307019635843 31.WangXGaoYTanJDevadasKRagupathyVTakedaKet al.. HIV-1 and HIV-2" exact="infections" post="induce autophagy in Jurkat and CD4+ T cells. Cell"/>
 <result pre="10.1128/JVI.02015-1729237845 34.BelzileJPSabalzaMCraigMClarkEMorelloCSSpectorDH. Trehalose, an mTOR-independent inducer of autophagy, inhibits human" exact="cytomegalovirus infection" post="in multiple cell types. J Virol. (2016) 90:1259â€&quot;77. 10.1128/JVI.02651-1526559848"/>
 <result pre="34.BelzileJPSabalzaMCraigMClarkEMorelloCSSpectorDH. Trehalose, an mTOR-independent inducer of autophagy, inhibits human cytomegalovirus" exact="infection" post="in multiple cell types. J Virol. (2016) 90:1259â€&quot;77. 10.1128/JVI.02651-1526559848"/>
 <result pre="36.WuQJiangDHuangCvan DykLFLiLChuHW. Trehalose-mediated autophagy impairs the anti-viral function of human" exact="primary" post="airway epithelial cells. PLoS ONE. (2015) 10:e0124524. 10.1371/journal.pone.012452425879848 37.BeatmanEOyerRShivesKDHedmanKBraultACTylerKLet"/>
 <result pre="Trehalose-mediated autophagy impairs the anti-viral function of human primary airway" exact="epithelial" post="cells. PLoS ONE. (2015) 10:e0124524. 10.1371/journal.pone.012452425879848 37.BeatmanEOyerRShivesKDHedmanKBraultACTylerKLet al.. West"/>
 <result pre="through interacting with Beclin1 to negatively regulate antiviral innate immunity." exact="Protein" post="Cell. (2014) 5:912â€&quot;27. 10.1007/s13238-014-0104-625311841 39.ReggioriFMonastyrskaIVerheijeMHCaliTUlasliMBianchiSet al.. Coronaviruses Hijack the"/>
 <result pre="LC3-Associated endocytosis facilitates beta-amyloid clearance and mitigates neurodegeneration in murine" exact="Alzheimer's disease." post="Cell. (2019) 178:536â€&quot;51 e514. 10.1016/j.cell.2019.05.05631257024 45.LewnardJALoNC. Scientific and ethical"/>
 <result pre="analogs as a promising strategy for the treatment of emerging" exact="viral" post="diseases. Pharmacol Res Perspect. (2017) 5:e00293. 10.1002/prp2.29328596841 60.CaoBParnellLADiamondMSMysorekarIU. Inhibition"/>
 <result pre="chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical"/>
 <result pre="diphosphate as adjunctive therapy for patients hospitalized with severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial."/>
 <result pre="as adjunctive therapy for patients hospitalized with severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial. JAMA"/>
 <result pre="without concomitant azithromycin among hospitalized patients testing positive for coronavirus" exact="disease" post="2019 (COVID-19). JAMA Cardiol. (2020). [Epub ahead of print]."/>
 <result pre="China. Lancet. (2020) 395:497â€&quot;506. 10.1016/S0140-6736(20)30183-531986264 68.CarratFVerguEFergusonNMLemaitreMCauchemezSLeachSet al.. Time lines of" exact="infection" post="and disease in human influenza: a review of volunteer"/>
 <result pre="(2020) 395:497â€&quot;506. 10.1016/S0140-6736(20)30183-531986264 68.CarratFVerguEFergusonNMLemaitreMCauchemezSLeachSet al.. Time lines of infection and" exact="disease" post="in human influenza: a review of volunteer challenge studies."/>
 <result pre="Lancet. (2015) 385:1729â€&quot;37. 10.1016/S0140-6736(14)62449-125640810 70.UyekiTMBernsteinHHBradleyJSEnglundJAFileTMFryAMet al.Clinical practice guidelines by the" exact="infectious diseases" post="society of America: 2018 update on diagnosis, treatment, chemoprophylaxis,"/>
 <result pre="anti-inflammatory drugs in the treatment of people with severe coronavirus" exact="disease" post="2019 (COVID-19): the perspectives of clinical immunologists from China."/>
 <result pre="J Surg. (2020) 77:206â€&quot;16. 10.1016/j.ijsu.2020.04.00132289472 77.LaiCCLiuYHWangCYWangYHHsuehSCYenMYet al.. Asymptomatic carrier state," exact="acute" post="respiratory disease, and pneumonia due to severe acute respiratory"/>
 <result pre="Surg. (2020) 77:206â€&quot;16. 10.1016/j.ijsu.2020.04.00132289472 77.LaiCCLiuYHWangCYWangYHHsuehSCYenMYet al.. Asymptomatic carrier state, acute" exact="respiratory" post="disease, and pneumonia due to severe acute respiratory syndrome"/>
 <result pre="10.1016/j.ijsu.2020.04.00132289472 77.LaiCCLiuYHWangCYWangYHHsuehSCYenMYet al.. Asymptomatic carrier state, acute respiratory disease, and" exact="pneumonia" post="due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2):"/>
 <result pre="carrier state, acute respiratory disease, and pneumonia due to severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths. J"/>
 <result pre="state, acute respiratory disease, and pneumonia due to severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2): Facts and myths. J Microbiol"/>
 <result pre="acute respiratory disease, and pneumonia due to severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2): Facts and myths. J Microbiol Immunol"/>
 <result pre="countries. JAMA. (2020) 323:1549â€&quot;50. 10.1001/jama.2020.416932176764 79.OtuAEbensoBLabonteRYayaS. Tackling COVID-19: can the" exact="African" post="continent play the long game?J Glob Health. (2020) 10:010339."/>
 <result pre="the epidemic curve of COVID-19. the case of Spain. Sci" exact="Total" post="Environ. (2020) 727:138761. 10.1016/j.scitotenv.2020.13876132330703 82.YamanaTSasikiran KandulaSPShamanJProjection of COVID-19 cases"/>
 <result pre="Med. (2020) 27:taaa021. 10.1093/jtm/taaa02132052846 87.AndersonRMMayRM. Vaccination and herd immunity to" exact="infectious diseases." post="Nature. (1985) 318:323â€&quot;9. 10.1038/318323a03906406 88.YuXYangR. COVID-19 transmission through asymptomatic"/>
 <result pre="Dis. (2020). [Epub ahead of print]. 10.1093/cid/ciaa450 91.JiatongSLanqinLWenjunL. COVID-19 epidemic:" exact="disease" post="characteristics in children. J Med Virol. (2020) 92:747â€&quot;54. 10.1002/jmv.2580732232980"/>
 <result pre="and older adults. Aging. (2016) 8:1167â€&quot;83. 10.18632/aging.10096227208415 95.van SeventerJMHochbergNSPrinciples of" exact="infectious" post="disease: transmission, diagnosis, prevention, and control. Int Encyclopedia Public"/>
 <result pre="regulating inflammasome activity and IL-1beta in LPS plus mechanical ventilation-induced" exact="acute" post="lung injury. Front Immunol. (2020) 11:207. 10.3389/fimmu.2020.0020732117318 97.TayaKHiroseKHamadaS. Trehalose"/>
 <result pre="al.. Opposing effects of fasting metabolism on tissue tolerance in" exact="bacterial" post="and viral inflammation. Cell. (2016) 166:1512â€&quot;25 e1512. 10.1016/j.cell.2016.07.02627610573"/>
 <result pre="effects of fasting metabolism on tissue tolerance in bacterial and" exact="viral" post="inflammation. Cell. (2016) 166:1512â€&quot;25 e1512. 10.1016/j.cell.2016.07.02627610573"/>
</results>
